CoChat

Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels

Leder, Benjamin Z., Rohrer, Jacqueline L., Rubin, Stephen D., Gallo, Jose, Longcope, Christopher · 2004 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 63 of the 68 references it cites were found in a registry or an index.

Abstract

As men age, serum testosterone levels decrease, a factor that may contribute to some aspects of age-related physiological deterioration. Although androgen replacement has been shown to have beneficial effects in frankly hypogonadal men, its use in elderly men with borderline hypogonadism is controversial. Furthermore, current testosterone replacement methods have important limitations. We investigated the ability of the orally administered aromatase inhibitor, anastrozole, to increase endogenous testosterone production in 37 elderly men (aged 62–74 yr) with screening serum testosterone levels less than 350 ng/dl. Subjects were randomized in a double-blind fashion to the following 12-wk oral regimens: group 1: anastrozole 1 mg daily (n = 12); group 2: anastrozole 1 mg twice weekly (n = 11); and group 3: placebo daily (n = 14). Hormone levels, quality of life (MOS Short-Form Health Survey), sexual function (International Index of Erectile Function), benign prostate hyperplasia severity (American Urological Association Symptom Index Score), prostate-specific antigen, and measures of safety were compared among groups. Mean ± sd bioavailable testosterone increased from 99 ± 31 to 207 ± 65 ng/dl in group 1 and from 115 ± 37 to 178 ± 55 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.054 group 1 vs. group 2). Total testosterone levels increased from 343 ± 61 to 572 ± 139 ng/dl in group 1 and from 397 ± 106 to 520 ± 91 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.012 group 1 vs. group 2). Serum estradiol levels decreased from 26 ± 8 to 17 ± 6 pg/ml in group 1 and from 27 ± 8 to 17 ± 5 pg/ml in group 2 (P < 0.001 vs. placebo for both groups and P = NS group 1 vs. group 2). Serum LH levels increased from 5.1 ± 4.8 to 7.9 ± 6.5 U/liter and from 4.1 ± 1.6 to 7.2 ± 2.8 U/liter in groups 1 and 2, respectively (P = 0.007 group 1 vs. placebo, P = 0.003 group 2 vs. placebo, and P = NS group 1 vs. group 2). Scores for hematocrit, MOS Short-Form Health Survey, International Index of Erectile Function, and American Urological Association Symptom Index Score did not change. Serum prostate-specific antigen levels increased in group 2 only (1.7 ± 1.0 to 2.2 ± 1.5 ng/ml, P = 0.031, compared with placebo). These data demonstrate that aromatase inhibition increases serum bioavailable and total testosterone levels to the youthful normal range in older men with mild hypogonadism. Serum estradiol levels decrease modestly but remain within the normal male range. The physiological consequences of these changes remain to be determined.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2003-031467

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. Med Lett Drugs Ther, 42, 49

Cited by

See all 149

Metadata

Authors
Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C.
Affiliations
  • Massachusetts General Hospital (US)
  • AstraZeneca (United States) (US)
  • AstraZeneca Pharmaceuticals (S.D.R., J.G.), Wilmington, Delaware 19850
  • University of Massachusetts Chan Medical School (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-03-01
Volume
89
Issue
3
Pages
1174-1180
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2117332496
Cited by
149
References
68
Citations by year
2026: 1 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 5 · 2017: 3 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 5
FWCI
7.20
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Center for Research Resources (K23 RR 16310, K23RR016310)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords
anastrozole, aromatase inhibitors, older men, androgen deficiency, testosterone replacement therapy, estradiol suppression, luteinizing hormone, sexual function, erectile function, benign prostatic hyperplasia, quality of life, adverse effects, drug safety, age-related testosterone decline, prostate-specific antigen, LH/FSH ratio
MeSH terms
Anastrozole, Aged, Aging, Enzyme Inhibitors, Estrogens, Humans, Hypogonadism, Male, Middle Aged, Nitriles, Quality of Life, Testosterone, Triazoles, Treatment Outcome, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels. https://app.cochat.ai/papers/10.1210/jc.2003-031467
The paper
Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C. (2004). Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-031467

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.